BT-001

N/A

Report date: 2025/11/22 20:00:09

Base Information

Drug NameBT-001
Drug Alias NameVV--CTLA-4oncolytic Vaccinia virus encoding CTLA-4 checkpoint inhibitorBT-001
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsMacrophage colony stimulating factor 2 stimulants
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Macrophage colony stimulating factor 2
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTransgene Sa
China Registration ClassN/A

Develop Information

Active CompaniesBioinvent International Ab
Inactive CompaniesTransgene Sa
Active IndicationsNeoplasms
Inactive IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A